GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmocann Global Ltd (XTAE:PMCN-M) » Definitions » Debt-to-Equity

Pharmocann Global (XTAE:PMCN-M) Debt-to-Equity : 0.51 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Pharmocann Global Debt-to-Equity?

Pharmocann Global's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪0.20 Mil. Pharmocann Global's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪0.19 Mil. Pharmocann Global's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₪0.76 Mil. Pharmocann Global's debt to equity for the quarter that ended in Dec. 2023 was 0.51.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pharmocann Global's Debt-to-Equity or its related term are showing as below:

XTAE:PMCN-M' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02   Med: 0.1   Max: 0.51
Current: 0.51

During the past 12 years, the highest Debt-to-Equity Ratio of Pharmocann Global was 0.51. The lowest was 0.02. And the median was 0.10.

XTAE:PMCN-M's Debt-to-Equity is ranked worse than
66.47% of 853 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs XTAE:PMCN-M: 0.51

Pharmocann Global Debt-to-Equity Historical Data

The historical data trend for Pharmocann Global's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmocann Global Debt-to-Equity Chart

Pharmocann Global Annual Data
Trend Dec09 Dec10 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.07 0.12 0.32 0.51

Pharmocann Global Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.23 0.32 0.24 0.51

Competitive Comparison of Pharmocann Global's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmocann Global's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmocann Global's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmocann Global's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pharmocann Global's Debt-to-Equity falls into.



Pharmocann Global Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pharmocann Global's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Pharmocann Global's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmocann Global  (XTAE:PMCN-M) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Pharmocann Global Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pharmocann Global's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmocann Global (XTAE:PMCN-M) Business Description

Traded in Other Exchanges
N/A
Address
Ramat Yishai, PO Box 305, Kiryat Tivon, ISR, 3601201
Pharmocann Global Ltd is an Israel-based company engaged in producing medical-related cannabis products which include oil, ointments, tablets, inhalers, rectal and vaginal suppositories, and pre-rolled cigarettes of various types of THC/CBD strains.

Pharmocann Global (XTAE:PMCN-M) Headlines

No Headlines